Bio-Thera Files for Approval of Avastin Biosimilar in Europe
November 25, 2020 at 05:08 AM EST
Bio-Thera Solutions of Guangzhou filed for European approval of its Avastin ® (bevacizumab) biosimilar including all Avastin indications. Bevacizumab is a humanized mAb that targets vascular endothelial growth factor (VEGF). The submission of BAT1706 is Bio-Thera's first MAA/BLA filing outside of China . Previously, the company was approved to market its Humira ® (adalimumab) biosimilar, Qletli ® in China for rheumatoid arthritis and other autoimmune diseases. More details.... Stock Symbol: (SHA: 688177) Share this with colleagues: // //
